Saimirra Innopharm Private Limited
ACTIVE
ISIN: INE0N3V07010
Issuer Details
Issuer Name
SAIMIRRA INNOPHARM PRIVATE L...
Type of Issuer
Non PSU
Sector
Healthcare
Coupon Rate
13%
Industry
Pharmaceuticals & Biotechnol...
Issuer nature
Other
Corporate Identity Number (CIN)
U24232TN2000PTC044315
Name of the Lead Manager
-
Registrar
Integrated Enterprises (Indi...
Name of Debenture Trustee
Catalyst Trusteeship Limited...
Instrument Details
Instrument name as on NSDL
13% SECURED UNRATED UNLISTED...
Face Value (in ₹)
1000000
Total Issue size( in ₹ Cr.)
15
Category of Instrument
PLAIN VANILLA DEBENTURES
Allotment Date
09-03-2023
Redemption Date
09-03-2026
Whether Secured or Unsecured
Secured
Put Option Date
01-11-2024
Call Option Date
-
Seniority in Repayment
Senior
Security Measures
Asset Coverage
Principal
Asset Percentage
100%
Details of Asset Cover
Issuers interests in all loans and advances provided to Delvin Formulations Pvt Ltd and Nuray Chemicals Pvt Ltd
Asset Type
Details of the security
Others, Please Specify
Personal Guarantees by Promoters and Ms. Lakshmi Arul
Immovable Assets
Survey no 167 Part Row Type no H2/6, New no 27 Thiruvanmiyur ,Chennai District
Immovable Assets
Survey Nos. 171, 172, 239 Part and 380 Part, Village: Pattaravakkam, Tehsil: Ambattur, District: Chennai
Immovable Assets
Immovable assets of SaiMirra Innopharm P. Ltd
Book Debts / Receivables
Issuers interests in all loans and advances provided to Delvin Formulations Pvt Ltd and Nuray Chemicals Pvt Ltd
Others, Please Specify
Pledge over 45.14% equity of Nuray Chemicals Pvt Ltd held by Jayaseelan J & Clan Laboratories Pvt Ltd
Others, Please Specify
Corporate Guarantee by Clan Laboratories Pvt Ltd
Others, Please Specify
Pledge over 66.67% equity of Delvin Formulations Pvt Ltd held by Jayaseelan J
Others, Please Specify
Corporate Gurantee by Thretha Investments and portfolio services pvt ltd
Others, Please Specify
Plege over all convertible preference shares, compulsorily convertible debentures and any other convertible security of the SaiMirra Innopharm P. Ltd and Nuray Chemicals Pvt Ltd ., held by Jayaseelan J , Clan Laboratories Pvt Ltd & Thretha Investments and portfolio services pvt ltd
Others, Please Specify
NDU provided by Mr. Shanmugham over his entire shareholding in Saimirra Innopharm pvt Ltd ,Nuray Chemicals Pvt Ltd and Delvin Formulations Pvt Ltd
Immovable Assets
Survey No. 3956/2 and 3957/6, No. A 202, Kesav Dugar Apartments, 1st Avenue, Kesavaperumalpuram, Chennai 600 028
Trust & Retention Account /Escrow Accounts
Charge over cashflows / receivables and ISRA in escrow account of SaiMirra Innopharm P. Ltd.
Immovable Assets
Oceanic Towers 1902, Hiranandani upscale Egattur, Chengalpattu Ditrict
Others, Please Specify
Pledge over 66.67% equity of Saimirra Innopharm pvt Ltd held by Jayaseelan J & Clan Laboratories Pvt Ltd
Immovable Assets
Plot no 50, Sri Swaminatha Nagar, Survey No: 1395/D, 1395/D120, Village: Thaiyur B Village, Tehsil: Chengalpattu
Disclaimer: Tap Bonds gathers data directly from the respective OBPP websites but does not guarantee its accuracy. We do not offer investment advice or endorse the purchase of any securities mentioned, nor do we warrant the reliability of the information collected.
Similar Bonds
About Saimirra Innopharm Private Limited bond with ISIN: INE0N3V07010
In the competitive landscape of fixed income securities, detailed and comprehensive information is vital for both investors and market analysts. This bond, identified by the unique ISIN INE0N3V07010, represents a significant financial instrument. Issued by SAIMIRRA INNOPHARM PRIVATE LIMITED, it comes with the following description: "13% SECURED UNRATED UNLISTED REDEEMABLE NON CONVERTIBLE DEBENTURE SERIES I DATE OF MATURITY 09/03/2026.". Although the bond is currently marked as active, its structure and historical context provide valuable insights into the world of debentures and non-convertible securities. The issuer, SAIMIRRA INNOPHARM PRIVATE LIMITED, classified as Non PSU, plays an essential role in the market despite some details such as sector, industry, and issuer nature not being explicitly provided. Key identifiers like the Corporate Identification Number (CIN) U24232TN2000PTC044315 further bolster its credibility. With a coupon rate of 13, this instrument has been meticulously managed with the assistance of Integrated Enterprises (India) Ltd., Chennai and under the oversight of Catalyst Trusteeship Limited (Formerly GDA Trusteeship Limited), ensuring a strong operational framework. Examining the technical specifications, the bond’s face value is 1000000 with an issue size of 15. It was allotted on 3/9/2023 and is scheduled for redemption on 3/9/2026. Categorized under "PLAIN VANILLA DEBENTURES" and defined as Secured, the instrument is structured to meet specific investment objectives. Although options such as call or put are not applicable in this instance, the core attributes remain detailed and robust. A critical element in evaluating any fixed income instrument is its credit rating. No credit rating information is available for this bond. This insight helps potential investors understand that while the ratings spectrum is broad, a lower rating can indicate higher risk, prompting careful consideration before investing. The security measures add another layer of assurance. The asset cover is described as follows: Issuers interests in all loans and advances provided to Delvin Formulations Pvt Ltd and Nuray Chemicals Pvt Ltd – a feature that, while requiring further inquiry for complete details, underscores the issuer’s commitment to providing some level of investor protection. Furthermore, the bond is supported by several documents. There are no additional documents available for this bond. These documents serve as a reference for additional details and provide transparency to interested parties. Additionally, there are similar bonds in the market such as the bond with ISIN INE0N3V07028 having a coupon rate of 13%. Such comparable instruments offer a broader perspective on market positioning and allow investors to perform benchmark analysis. This detailed description is crafted to meet rigorous content standards and to offer exhaustive insights into every facet of the bond’s structure. Investors, analysts, and researchers alike can derive substantial value from this narrative, which underscores both the instrument’s inherent characteristics and its broader market positioning. Such elaborate coverage enhances investor confidence by providing a rich, comprehensive content base. Every element from issuance details to security measures and comparative insights is meticulously presented to facilitate an informed and robust market understanding.